Oramed
{{Short description|Pharmaceutical company of Israel}}
{{Use dmy dates|date=July 2023}}
{{Infobox company
| name = Oramed Pharmaceuticals Inc.
| logo = Oramed logo 2022.svg
| caption =
| trading_name =
| native_name =
| native_name_lang =
| romanized =
| former type =
| type = Public
| traded_as = {{Nasdaq|ORMP}}
Russell Microcap Index component
{{TLV|ORMP}}
| industry = Biotech
| fate =
| predecessor =
| successor =
| foundation = {{Start date and age|2006}}
| founder =
| defunct =
| location_city = Jerusalem
| location_country =
| locations =
| area_served =
| key_people = Nadav Kidron (CEO)
| products =
| production =
| services =
| revenue =
| operating_income =
| net_income =
| assets =
| equity =
| owner =
| num_employees =
| parent =
| divisions =
| subsid =
| homepage = {{URL|oramed.com}}
| footnotes =
| intl =
| bodystyle =
}}
Oramed Pharmaceuticals Inc. ({{Langx|he|אורמד}}), is a publicly traded company engaged in the development of oral drug delivery systems – most notably an oral insulin capsule for treating type 2 diabetes. The company was founded in 2006 and is headquartered in Jerusalem. Its shares are listed on the NASDAQ Capital Market and the Tel Aviv Stock Exchange.
History
Oramed Pharmaceuticals was founded in 2006 by Miriam Kidron, a scientist at the Hadassah University Hospital in Jerusalem, and her son Nadav Kidron.{{cite news|last=Weinreb|first=Gali|title=Insulin pill co Oramed jumps on Nasdaq listing plans|url=http://www.globes.co.il/serveen/globes/docview.asp?did=1000814732&fid=1725|accessdate=16 February 2013|newspaper=Globes|date=15 January 2013}}{{cite web|last=Blackburn|first=Nicky|title=Israeli patent moves closer to achieving oral insulin treatment|url=http://israel21c.org/health/israeli-patent-moves-closer-to-achieving-oral-insulin-treatment/|publisher=Israel21c|accessdate=16 February 2013|date=24 June 2007}}
Product pipeline
Oramed considers its flagship product to be an oral insulin capsule developed to treat sufferers of type 2 diabetes. The Company is currently conducting Phase 3 trials, under the FDA, for oral insulin in Type 2 diabetes.
In addition to the oral insulin capsule, Oramed is developing an exenatide-based capsule designed to balance blood sugar levels and control appetite, and is conducting clinical trials for the treatment of NASH with oral insulin.{{Cite web|title=Oramed Initiates Phase 2 NASH Trial of Oral Insulin|url=https://www.prnewswire.com/news-releases/oramed-initiates-phase-2-nash-trial-of-oral-insulin-301183628.html|access-date=26 August 2021|website=www.prnewswire.com|language=en}}
In 2021, Oramed created a subsidiary, Oravax Medical, to bring an oral Covid-19 vaccine to market.{{Cite web|title=Oramed Forms a Joint Venture, Oravax Medical Inc., for the Development of Novel Oral COVID-19 Vaccines|url=https://www.prnewswire.com/news-releases/oramed-forms-a-joint-venture-oravax-medical-inc-for-the-development-of-novel-oral-covid-19-vaccines-301250990.html|access-date=26 August 2021|website=www.prnewswire.com|language=en}}
In January 2023, Phase 3 trial of Oramed's orally administered insulin for Type 2 diabetes patients failed thus causing the share price to plunge.{{cite news|url=https://en.globes.co.il/en/article-oramed-plunges-after-reporting-trial-failure-1001435437|title=Oramed plunges after reporting trial failure|publisher=Globes|access-date=4 May 2023}}
In May 2023, Ben Shapiro invested $4.7 million and was named to the board of directors.{{cite news|url=https://www.bloomberg.com/news/articles/2023-05-02/conservative-pundit-shapiro-takes-stake-in-israeli-drug-company?leadSource=uverify%20wall&sref=xhJDrP3t|title=Conservative Pundit Ben Shapiro Invests $4.7 Million in Israeli Drug Company|publisher=Bloomberg|access-date=4 May 2023}}
See also
References
{{Reflist}}
{{Israel NASDAQ}}{{TA 100 companies}}
Category:Biotechnology companies of Israel
Category:Companies listed on the Nasdaq
Category:Pharmaceutical companies of Israel